Table 2.
Blood pressure characteristics at baseline for the total study population and stratified for reaching the blood pressure treatment target goal
| All n = 508 |
Below targetΔ n = 58 |
Above targetΔ n = 450 |
|
|---|---|---|---|
| Systolic blood pressure (mmHg) | 152 ± 27 | 114 ± 12 | 157 ± 25 |
| Diastolic blood pressure (mmHg) | 83 ± 14 | 68 ± 8 | 85 ± 13 |
| Anti-hypertensive drug types (%) | |||
| ACE-inhibitor | 43 | 60 | 40 |
| Angiotensin II-inhibitor | 20 | 10 | 21 |
| Beta-blocker | 39 | 31 | 40 |
| Calcium antagonist | 45 | 22 | 48 |
| Diuretics | 48 | 52 | 48 |
| Other* | 14 | 7 | 15 |
| Number of anti-hypertensive drug types (%) | |||
| 0 | 8 | 9 | 8 |
| 1 | 26 | 35 | 24 |
| 2 | 28 | 33 | 28 |
| ≥ 3 | 38 | 23 | 40 |
Systolic (SBP) and diastolic blood pressure (DBP) are presented as mean ± standard deviation (SD).
Δ Below the target was defined as SBP < 130 and DBP < 80 mmHg and above the target as SBP ≥ 130 and/or DBP ≥ 80 mmHg. * Defined as the prescription of alpha blocker, vasodilator, and/or central working agent.